Brief: Ashlins Pharmaceuticals And Lee's Pharm Announce Exclusive License And Supply Agreement Valued At Up To $31 Million
21/07/2026 12:28
BRIEF-Ashlins Pharmaceuticals And Lee's Pharm Announce Exclusive License And Supply Agreement Valued At Up To $31 Million July 21 (Reuters) - Lee's Pharmaceutical Holdings Ltd 0950.HK:
ASHLINS PHARMACEUTICALS AND LEE'S PHARM ANNOUNCE EXCLUSIVE LICENSE AND SUPPLY AGREEMENT VALUED AT UP TO $31 MILLION
ASHLINS PHARMACEUTICALS: UNDER AGREEMENT, ASHLINS HAS OBTAINED EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE CERTAIN DRUG PRODUCTS
Source text: ID:nBwbCG2WGa
Further company coverage: 0950.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lee's Pharmaceutical Holdings
See all newsHong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product sales
Brief: Lee's Pharmaceutical Expects H1 Net Profit Of HK$85 Million-HK$95 Million
Brief: Lee's Pharmaceutical Says Investigational New Drug Application For ADC Project ZK2401 Accepted By NMPA
Brief: Ashlins Pharmaceuticals And Lee's Pharm Announce Exclusive License And Supply Agreement Valued At Up To $31 Million
Brief: Lee's Pharmaceutical Says Entered Licensing Agreement With Ashlins Ocular Pharmaceuticals